Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Zillow Group Inc Class C — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Zillow Group Inc Class C trades at $32.33 (market cap $7.36B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 5.4× Zillow Group Inc Class C's market cap. Which is the better fit depends on your goals.
| ALNY | Z | |
|---|---|---|
Market Cap | $39.89B | $7.36B |
Sector | Health | Media |
52-Week High | $491.22 | $90.35 |
52-Week Low | $278.09 | $29.41 |
Enterprise Value | $38.15B | $7.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Zillow Group (Z) trades at $32.19, down 3.74% on the day. The stock shows mixed technical signals with a neutral overall stance. Fundamentally, the company reported revenue of $2.58 billion in 2025 with a net income of $23 million, marking a return to profitability. However, a high P/E ratio of 128.76 indicates significant growth expectations are priced in. Recent news is dominated by multiple securities class action lawsuits filed against the company.
The outlook is clouded by legal risks, though analyst consensus remains optimistic with a $63 price target. The primary opportunity lies in the company's strong revenue growth and high gross margins, but investors must weigh this against the overhang from litigation and the stock's demanding valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
